Researchers sought to determine whether selinexor could be safely combined with pomalidomide and dexamethasone in heavily pretreated patients with multiple myeloma. The following article features ...
The prognosis of relapsed and refractory multiple myeloma (RRMM) that is refractory to bortezomib and lenalidomide is very poor wherein the median survival is between 3 and 9 months. We did this ...
SAN DIEGO -- In a randomized trial, pomalidomide (Pomalyst) significantly reduced severe nosebleeds in patients with hereditary hemorrhagic telangiectasia (HHT), a condition with no approved therapy.
Pomalidomide is an oral IMiD immunomodulatory agent with significant activity in RRMM. 9 With direct tumoricidal, potent immune-activating, antiangiogenic and anti-inflammatory activities, ...
Discover comprehensive details about Pomalidomide, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...
The appraisal committee reviewed the data available on the clinical and cost effectiveness of pomalidomide, having considered evidence on the nature of multiple myeloma and the value placed on the ...
The US Food and Drug Administration (FDA) has granted accelerated approval to pomalidomide (Pomalyst, Bristol-Myers Squibb) for the treatment of AIDS-related Kaposi sarcoma that is resistant to highly ...
Patients with multiple myeloma progressing on current therapies have limited treatment options. Pomalidomide (CC4047), an immunomodulatory drug, has significant activity in relapsed myeloma and ...
Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma Sixty patients were enrolled.
The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. The immunomodulatory ...
On February 8, 2013, the US Food and Drug Administration approved pomalidomide (Pomalyst) for the treatment of patients with multiple myeloma who have received at least 2 previous myeloma therapies, ...
1.1 Pomalidomide, in combination with low‑dose dexamethasone, is recommended as an option for treating multiple myeloma in adults at third or subsequent relapse; that is, after 3 previous treatments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results